| Literature DB >> 17409409 |
Simon A Gayther1, Honglin Song, Susan J Ramus, Susan Krüger Kjaer, Alice S Whittemore, Lydia Quaye, Jonathan Tyrer, Danielle Shadforth, Estrid Hogdall, Claus Hogdall, Jan Blaeker, Richard DiCioccio, Valerie McGuire, Penelope M Webb, Jonathan Beesley, Adele C Green, David C Whiteman, Marc T Goodman, Galina Lurie, Michael E Carney, Francesmary Modugno, Roberta B Ness, Robert P Edwards, Kirsten B Moysich, Ellen L Goode, Fergus J Couch, Julie M Cunningham, Thomas A Sellers, Anna H Wu, Malcolm C Pike, Edwin S Iversen, Jeffrey R Marks, Montserrat Garcia-Closas, Louise Brinton, Jolanta Lissowska, Beata Peplonska, Douglas F Easton, Ian Jacobs, Bruce A J Ponder, Joellen Schildkraut, C Leigh Pearce, Georgia Chenevix-Trench, Andrew Berchuck, Paul D P Pharoah.
Abstract
High-risk susceptibility genes explain <40% of the excess risk of familial ovarian cancer. Therefore, other ovarian cancer susceptibility genes are likely to exist. We have used a single nucleotide polymorphism (SNP)-tagging approach to evaluate common variants in 13 genes involved in cell cycle control-CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, and CDKN2D-and risk of invasive epithelial ovarian cancer. We used a two-stage, multicenter, case-control study. In stage 1, 88 SNPs that tag common variation in these genes were genotyped in three studies from the United Kingdom, United States, and Denmark ( approximately 1,500 cases and 2,500 controls). Genotype frequencies in cases and controls were compared using logistic regression. In stage 2, eight other studies from Australia, Poland, and the United States ( approximately 2,000 cases and approximately 3,200 controls) were genotyped for the five most significant SNPs from stage 1. No SNP was significant in the stage 2 data alone. Using the combined stages 1 and 2 data set, CDKN2A rs3731257 and CDKN1B rs2066827 were associated with disease risk (unadjusted P trend = 0.008 and 0.036, respectively), but these were not significant after adjusting for multiple testing. Carrying the minor allele of these SNPs was found to be associated with reduced risk [OR, 0.91 (0.85-0.98) for rs3731257; and OR, 0.93 (0.87-0.995) for rs2066827]. In conclusion, we have found evidence that a single tagged SNP in both the CDKN2A and CDKN1B genes may be associated with reduced ovarian cancer risk. This study highlights the need for multicenter collaborations for genetic association studies.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17409409 DOI: 10.1158/0008-5472.CAN-06-3261
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701